January 14th, 2025 | 07:55 CET
Qiagen, Vidac Pharma, and Bayer with groundbreaking news
In the years to come, biotechnology will play a central role in solving global challenges. From the development of innovative therapies to sustainable agriculture and biobased industries, biotechnology combines science and technology to make the world more sustainable and efficient. As a driver of growth and innovation, it offers enormous opportunities for companies and investors who want to actively shape the future.
time to read: 3 minutes
|
Author:
Stefan Feulner
ISIN:
QIAGEN NV EO -_01 | NL0012169213 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619 , BAYER AG NA O.N. | DE000BAY0017
Table of contents:

"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Bayer – The end of the dry spell
The downward trend of the crisis-ridden pharmaceutical and agricultural giant seems to have been stopped for the time being. After hitting a low of EUR 18.40 in November last year, Bayer shares fought their way up to the horizontal resistance level of EUR 20.50. A break of this prominent line would provide a buy signal with a follow-up potential up to the zone of around EUR 25.
The price of the Leverkusen-based company received a boost from a report by its biotech subsidiary BlueRock, which announced a breakthrough in the development of a new method for combating Parkinson's. The cell therapy bemdaneprocel will soon begin a Phase 3 study relevant to approval, as the Leverkusen-based pharmaceutical and agricultural group Bayer announced. The study will follow on directly from the Phase 1 study and was planned in close consultation with the US Food and Drug Administration after evaluating the results. The study is scheduled to start in the first half of the year and will involve around 102 patients with moderate Parkinson's disease.
Bayer secured the treatment technology in 2019 through its acquisition of BlueRock. According to the companies, this is the first Phase 3 study worldwide for a Parkinson's therapy developed from allogeneic pluripotent stem cells. The aim of bemdaneprocel is to replace lost dopamine-producing nerve cells. These cells are derived from pluripotent stem cells that originally came from human embryonic stem cells and are then implanted in the patient's brain. There, they are intended to repair damaged neural networks and restore both motor and non-motor functions.
Vidac Pharma – Further milestones
Since the end of May of the past stock market year 2024, shares of the biopharmaceutical oncology company have risen by approximately 275% to EUR 0.74. According to the analyst firm Sphene Capital, the price target, which was already set around six months ago, is EUR 4.90, offering a further price potential of 562%.
It is worth noting that since the analysis, Vidac Pharma has achieved further milestones in its business development. For example, the US Patent and Trademark Office expanded the patent protection for the active ingredients of the oncology drug candidates VDA-1102 and CDA-1275. The expansion covers, among other things, metastases of prostate cancer, pancreatic cancer, as well as colon, cervical, and lung cancer.
The Company, led by Max Herzberg, one of the founders of the Israeli life sciences industry, was able to report further groundbreaking news at the end of the year with the receipt of the final report from the Helsinki Committee at Beilinson Hospital on its groundbreaking clinical study on cutaneous T-cell lymphoma (CTCL).
There is currently no standard treatment for the condition, which causes severe skin inflammation and lesions caused by cancerous T-cells in the blood and lymphatic system. The Company's innovative ointment VDA-1102 aims to block the hyperglycolysis typical of cancer cells while providing a targeted and effective treatment option.
The report, submitted to the Israeli Ministry of Health, highlights promising results and enables the Company to move on to a crucial Phase 2/3 study. A successful outcome of this phase would be a significant step towards product registration.
Qiagen – On to new all-time highs
The chart of the Hilden-based company, which develops solutions for sample preparation and analysis of biological materials, also looks promising. Qiagen's products and technologies are used in molecular diagnostics, research, and forensics to isolate, analyse and interpret DNA, RNA and proteins.
Since the interim low at EUR 33.75 in early November, Qiagen's stock chart has formed an ascending triangle. If the horizontal resistance at EUR 44.78 is broken to the upside, the next price target is at the all-time high at EUR 53.15. The stock is receiving tailwinds from the trend-following MACD indicator and the Relative Strength Index (RSI), both of which have issued "Buy" signals.
Qiagen also provided a "Buy" signal from a fundamental perspective by rewarding its shareholders through a synthetic share repurchase of up to EUR 300 million. This involves a capital measure combining a direct capital repayment with a reverse stock split. The process is to be completed by the end of January and includes the repayment of an amount corresponding to the planned volume at the beginning of 2024. At least USD 1 billion is expected to be returned to shareholders by the end of 2028.
According to Qiagen, the synthetic share repurchase will enable a faster and more efficient return of cash than traditional buyback programs. In addition, earnings per share will increase due to the reduction in the number of shares outstanding.
After a long dry spell, the pharmaceutical and agricultural giant Bayer's stock is on the verge of a strong buy signal. Qiagen's stock could start an attack on new all-time highs following a breakout from its horizontal resistance. Vidac Pharma is taking another step towards product registration with its oncology drug candidate VDA-1102.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.